List of Oleptro drug patents
Oleptro is owned by Angelini Pharma.
Oleptro contains Trazodone Hydrochloride.
Oleptro has a total of 2 drug patents out of which 0 drug patents have expired.
Oleptro was authorised for market use on 02 February, 2010.
Oleptro is available in tablet, extended release;oral dosage forms.
Oleptro can be used as method of treating depression.
The generics of Oleptro are possible to be released after 13 March, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8133893 | ANGELINI PHARMA | Trazodone and trazodone hydrochloride in purified form |
Mar, 2029
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7829120 | ANGELINI PHARMA | Trazodone composition for once a day administration |
Mar, 2027
(3 years from now) | |
Drugs and Companies using TRAZODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 02 February, 2010
Treatment: Method of treating depression
Dosage: TABLET, EXTENDED RELEASE;ORAL
OLEPTRO family patents
30
United States
6
Japan
5
Canada
4
Argentina
4
Korea, Republic of
4
European Union
3
Spain
3
Denmark
3
China
3
Brazil
3
Israel
3
Australia
2
Hong Kong
2
Poland
2
Ukraine
2
EA
2
Norway
2
Portugal
2
Taiwan
2
Georgia
2
Ecuador
2
South Africa
2
Slovenia
1
Italy
1
Malaysia
1
Russia
1
New Zealand
1
Croatia
1
Cyprus
1
Mexico
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic